ClearPoint Neuro, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ClearPoint Neuro, Inc. (Nasdaq:CLPT) is a global device, cell, and gene therapy-enabling company offering precise navigation and delivery solutions to the brain and spine. Founded in 1998 and headquartered in Solana Beach, California, the company provides the ClearPoint Neuro Navigation System, an FDA-cleared and CE-marked integrated platform for minimally invasive procedures including deep brain stimulation electrode insertion, biopsy needle placement, laser catheter ablation via the ClearPoint PRISM Laser Therapy System, and pharmaceutical infusions; SmartFrame OR for stereotactic neurosurgery; ClearPoint Maestro Brain Model for procedural planning; ClearPoint Array Platform; associated disposables and software; and preclinical development services through ClearPoint Advanced Laboratories (CAL), including GLP studies for central nervous system (CNS) drug delivery. It serves neurosurgeons, biopharma partners conducting over 60 gene and cell therapy programs, research centers, and patients targeting complex neurological disorders such as tumors, epilepsy, and Parkinson's disease; operations span healthcare and research facilities in North America, Europe, Asia, South America, with regulatory approvals in 34 countries including recent expansions in Canada, Hong Kong, and Taiwan. Recent developments include FDA 510(k) clearance in 2025 for ClearPoint PRISM compatibility with 1.5T MRI scanners, operational launch of the CAL facility in Torrey Pines, California, prototype demonstration of a Robotic Neuro-Navigation System integrating KUKA LBR Med arm for MRI, CT, and robotic workflows, a note financing arrangement with Oberland Capital providing up to $110 million including $30 million initially funded in 2025, and completion of the acquisition of IRRAS Holdings, Inc. on November 20, 2025 for $5 million cash and 1.325 million shares, adding the IRRAflow active fluid-exchange system for intracranial hemorrhage management, over 50 customers, and expanded commercial scale in neurocritical care.
Company News
ClearPoint Neuro Q2 Earnings Call Highlights
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates
ClearPoint Neuro Q2 Earnings Call Highlights
ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro, Inc. (CLPT) Q1 2026 Earnings Call Transcript
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates
ClearPoint Neuro Q1 Earnings Call Highlights
ClearPoint Neuro Reports First Quarter 2026 Results
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
Here Are Friday’s Top Wall Street Analyst Research Calls: Applied Materials, Devon Energy, Epam Systems, HubSpot, Nike, Shake Shack, Tapestry, Qualcomm, and More
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026